Opto Circuits subsidiary ready to launch its solutions for treating PAD in Germany

Image
Announcement Corporate
Last Updated : Jan 20 2013 | 1:43 AM IST

Opto Circuits (India) Ltd.’s Bonn-based subsidiary Eurocor GmbH presented its latest development in second generation PTA balloon technology – FREEWAY 014™ and FREEWAY 035™ – to the German market for the very first time at the LINC (Leipzig Interventional Course) on 20 January 2011. The two new products already premiered in London in November 2010.

The German launch of Eurocor’s new FREEWAY products is scheduled to take place at the “Symposium on drug-coated balloons for peripheral interventions: SFA and below the knee”. International experts will be presenting and discussing the latest developments in connection with treatment involving drug-eluting balloons at this symposium.

Expert Discussion

The scientific debate will be headed by the renowned physician and consultant angiologist from Berlin, Prof. Dr. Karl-Ludwig Schulte. Presentations will include a live transmission of an intervention involving a drug-eluting balloon as well as a paper delivered by the cell biologist PD Dr. Kirsten Peters from Rostock on the unique new coating technology. Lectures by other well-known physicians on the advantages of drug-eluting balloons to treat various indications, including below-the-knee dilations, will go to round off the programme.

Alternative to Amputation

FREEWAY 014™ was primarily developed for treating critical limb ischaemia associated with peripheral arterial disease (PAD). The primary amputation rate among diabetes mellitus patients with critical limb ischaemia linked to PAD can amount to as much as 40%. Thanks to Eurocor’s FREEWAY® DEB balloon interventionalists now have access to a treatment option that constitutes a valid alternative to amputation and can additionally help to save up to US$50,000 per patient per year.

“We are delighted to be able to present our latest developments to a large specialist audience in Leipzig. FREEWAY is the next logical step of our successful Eurocor technologies.” said Katja Hausner, Director Business Affairs at Eurocor.

About: Eurocor GmbH
Eurocor GmbH is a rapidly growing European Life Sciences Technology corporation specialising in the research, development and manufacture of interventional cardiology products. Eurocor is providing interventional cardiologists with innovative, coronary stent technologies and special cardiovascular devices.

The products manufactured by the company in Bonn are used in minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Strong research and development, close collaboration with clinicians, outstanding quality standard philosophy and global scientific alliances lead to optimisation of clinically effective technologies. For more information, please visit www.eurocor.de.

Follow us at http://twitter.com/Eurocor_Germany

About: Opto Circuits (India) Limited
Website: www.optoindia.com
Opto Circuits (India) Ltd. (OCI) is an MNC in the business of design, development, manufacture and marketing of healthcare equipment and medical interventional products. The product profile includes USFDA-listed, CE-marked cardiac and vital signs monitoring systems, anesthesia and respiratory care equipment, automated external defibrillators, stents, catheters, body implants and consumables. Some of OCI’s well-known brands are Cardiac Science, Criticare, Eurocor, Ormed, Mediaid and Unetixs.  The company’s key markets are North America, Europe and BRIC countries.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 21 2011 | 6:55 PM IST

Next Story